Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment.
Yan TanYingying LiYi-Xin QuYuanye SuYongbo PengZilong ZhaoTing FuXue-Qiang WangWeihong TanPublished in: ACS applied materials & interfaces (2020)
High levels of heat shock protein 70 (HSP70) in tumors are commonly associated with poor prognosis, enhanced doxorubicin (DOX)-induced cardiotoxicity, and even drug resistance in DOX-related cancer chemotherapy. Several peptides possess remarkable protein inhibition and chemosensitization effects, which are attributed to their specific targeting ability against HSP70. However, the inherent poor cell penetration capacity considerably restricts the biomedical applications of these peptides. We herein describe the design and development of anti-MUC1 aptamer-peptide conjugates (ApPCs) as targeted chemosensitizers to overcome the above-mentioned issues. Moreover, DOX could be loaded on the ApPC to deliver the DOX-enclosed agent ApPC-DOX, which simultaneously acts as a targeted chemosensitizer and anticancer agent for combating drug resistance in breast cancer therapy. This innovative, engineered biocompatible conjugate not only enhances the sensitivity of DOX-resistant cells but also alleviates cardiotoxicity of DOX in vivo, highlighting the success of this targeted chemosensitizer strategy.
Keyphrases
- cancer therapy
- heat shock protein
- drug delivery
- poor prognosis
- heat shock
- long non coding rna
- gold nanoparticles
- sensitive detection
- amino acid
- induced apoptosis
- single cell
- papillary thyroid
- stem cells
- drug release
- cell death
- ionic liquid
- cell proliferation
- cell cycle arrest
- high glucose
- oxidative stress
- radiation therapy
- squamous cell carcinoma
- magnetic nanoparticles
- cell therapy
- endothelial cells
- bone marrow
- endoplasmic reticulum stress
- label free
- pi k akt
- rectal cancer